Our development pipeline platform - directly reprogrammed neural precursor cells (drNPC™) - are neural precursor cells that are made from reprogramming cells that are harvested from the patient. drNPCs have been shown in vitro and in vivo models to specifically become neurons, oligodendrocytes and astrocytes, the basic building blocks of the central nervous system (brain and spinal cord). Through a grant awarded by the Canadian Institutes of Health Research (CIHR) in 2014, Jan-Eric Ahlfors and his team forged a collaboration with Key Opinion Leaders (KOLs) in the fields of neural stem cells, neuroscience and neurosurgery, for the independent evaluation of the drNPCs. Results were presented at the ISSCR in 2016 and 2017. 




Our Regeneration Matrix™  (RMx™)  under development (not approved for commercial use) is a novel self-assembling 3-dimensional biomaterial with intricate physical characteristics that aim to mimic the matrix in regenerating tissues. The goal in development will be to assess the ability of RMx™ placed in a site of injury to kick-start the regeneration process in damaged or injured tissue. In preclinical studies to-date, Regeneration Matrix™ has been shown to promote regeneration and prevent scar tissue formation.




The manufacturing process of the drNPC™ family of cells under development consists of a fully automated process that will allow for large scale production of therapeutic regenerative medicine cell products. Quality is critical to the successful development of our therapies.  We are therefore focusing on integrating a scalable, efficient, and high-quality cell manufacturing process, along with quality control, storage and distribution. We use only somatic cells in the manufacturing process. Somatic cells are the "everyday" cells that make up our body: they are ethical in that they do not involve the use of any embryonic or fetal cells or other material from these sources. We also use no animal components, viruses or bacteria in our production process.